CM Management LLC Purchases 40,000 Shares of Coya Therapeutics, Inc. (NASDAQ:COYA)

Key Points

• CM Management LLC increased its stake in Coya Therapeutics by 25.0%, acquiring an additional 40,000 shares, and now owns approximately 1.20% of the company worth $1.29 million.
• Coya Therapeutics is now rated as a "Moderate Buy" with an average target price of $16.50, as issued by several analysts, including Chardan Capital and Lake Street Capital.
• The company's recent quarterly earnings reported an EPS of ($0.44), meeting expectations, with substantial revenue of $257.88 million, surpassing forecasts.

CM Management LLC grew its holdings in Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) by 25.0% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 200,000 shares of the company's stock after acquiring an additional 40,000 shares during the quarter. CM Management LLC owned 1.20% of Coya Therapeutics worth $1,294,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Dauntless Investment Group LLC acquired a new stake in Coya Therapeutics during the 1st quarter valued at approximately $1,083,000. DME Capital Management LP increased its holdings in shares of Coya Therapeutics by 29.2% during the fourth quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock valued at $9,434,000 after acquiring an additional 372,414 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Coya Therapeutics in the 4th quarter worth $74,000. Northern Trust Corp grew its position in Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company's stock valued at $164,000 after purchasing an additional 3,099 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock valued at $30,000 after purchasing an additional 4,777 shares in the last quarter. 39.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on COYA shares. D. Boral Capital reissued a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a research report on Thursday, July 24th. Wall Street Zen cut shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Chardan Capital reissued a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Tuesday, July 1st. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a report on Monday, June 9th. Finally, Lake Street Capital started coverage on shares of Coya Therapeutics in a report on Wednesday, July 9th. They set a "buy" rating and a $16.00 target price on the stock. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $16.50.

Coya Therapeutics Price Performance

Coya Therapeutics stock traded down $0.02 during mid-day trading on Friday, reaching $6.08. 14,985 shares of the stock traded hands, compared to its average volume of 73,859. The stock has a market capitalization of $101.72 million, a PE ratio of -5.68 and a beta of 0.26. The business's 50-day moving average is $5.93 and its 200-day moving average is $6.08. Coya Therapeutics, Inc. has a 12-month low of $4.65 and a 12-month high of $10.24.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.44). The business had revenue of $257.88 million for the quarter, compared to the consensus estimate of $2.63 million. Equities analysts anticipate that Coya Therapeutics, Inc. will post -1.15 EPS for the current fiscal year.

Coya Therapeutics Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.